Advertisement
Research ArticleArticle

Preclinical Species and Human Disposition of PF-04971729, a Selective Inhibitor of the Sodium-Dependent Glucose Cotransporter 2 and Clinical Candidate for the Treatment of Type 2 Diabetes Mellitus

Amit S. Kalgutkar, Meera Tugnait, Tong Zhu, Emi Kimoto, Zhuang Miao, Vincent Mascitti, Xin Yang, Beijing Tan, Robert L. Walsky, Jonathan Chupka, Bo Feng and Ralph P. Robinson
Drug Metabolism and Disposition September 2011, 39 (9) 1609-1619; DOI: https://doi.org/10.1124/dmd.111.040675

Article Information

vol. 39 no. 9 1609-1619
DOI 
https://doi.org/10.1124/dmd.111.040675
PubMed 
21690265
Published By 
American Society for Pharmacology and Experimental Therapeutics
Print ISSN 
0090-9556
Online ISSN 
1521-009X
History 
  • Received May 15, 2011
  • Accepted June 20, 2011
  • Published online August 19, 2011.

Article Versions

Copyright & Usage 
Copyright © 2011 by The American Society for Pharmacology and Experimental Therapeutics

Author Information

  1. Amit S. Kalgutkar,
  2. Meera Tugnait,
  3. Tong Zhu,
  4. Emi Kimoto,
  5. Zhuang Miao,
  6. Vincent Mascitti,
  7. Xin Yang,
  8. Beijing Tan,
  9. Robert L. Walsky,
  10. Jonathan Chupka,
  11. Bo Feng and
  12. Ralph P. Robinson
  1. Pharmacokinetics, Dynamics and Metabolism Department (A.S.K., M.T., T.Z., E.K., Z.M., X.Y., B.T., R.L.W., J.C., B.F.) and Worldwide Medicinal Chemistry (V.M., R.P.R.), Pfizer Global Research and Development, Groton, Connecticut
  1. Address correspondence to:
    Dr. Amit S. Kalgutkar, Pharmacokinetics, Dynamics, and Metabolism Department, Pfizer Global Research and Development, Groton, CT 06340. E-mail: amit.kalgutkar{at}pfizer.com
View Full Text

Statistics from Altmetric.com

Article usage

Article usage: August 2017 to October 2024

AbstractFullPdf
Aug 2017103523
Sep 2017113620
Oct 201784921
Nov 201763720
Dec 201775317
Jan 201876119
Feb 201894316
Mar 2018233923
Apr 2018174316
May 201835019
Jun 2018103912
Jul 20186238
Aug 201893718
Sep 20183144
Oct 201855025
Nov 201864711
Dec 2018491616
Jan 20192922
Feb 20193066
Mar 201950169
Apr 20193877
May 20196038
Jun 201931410
Jul 201921116
Aug 201940143
Oct 20194947
Nov 20193632
Dec 20195955
Jan 20205553
Feb 20201753
Mar 20202313
May 20201545
Jun 20202045
Jul 20201411
Aug 20201113
Sep 20203723
Oct 20202286
Nov 20202534
Dec 20203634
Jan 20212767
Feb 20212786
Mar 20213963
Apr 20213765
May 20215285
Jun 20216485
Jul 20214296
Aug 2021351111
Sep 20211631
Oct 20213683
Nov 20212078
Dec 20214543
Jan 20222966
Feb 20221832
Mar 20225430
Apr 202244124
May 20225155
Jun 20223123
Jul 20222935
Aug 20223634
Sep 20222534
Oct 20223051
Nov 20225688
Dec 20221663
Jan 20232666
Feb 20232131
Mar 20233077
Apr 20232326
May 202333410
Jun 20231654
Jul 202335515
Aug 20231425
Sep 20233135
Oct 20233420
Nov 20231911
Dec 20235064
Jan 20245044
Feb 20243881
Mar 20244623
Apr 20244655
May 2024105100
Jun 20243736
Jul 202434122
Aug 202468410
Sep 20244954
Oct 20242702

Back to top

In this issue

Download PDF
Article Alerts
Email Article
Citation Tools

Research ArticleArticle

Preclinical Species and Human Disposition of PF-04971729, a Selective Inhibitor of the Sodium-Dependent Glucose Cotransporter 2 and Clinical Candidate for the Treatment of Type 2 Diabetes Mellitus

Amit S. Kalgutkar, Meera Tugnait, Tong Zhu, Emi Kimoto, Zhuang Miao, Vincent Mascitti, Xin Yang, Beijing Tan, Robert L. Walsky, Jonathan Chupka, Bo Feng and Ralph P. Robinson
Drug Metabolism and Disposition September 1, 2011, 39 (9) 1609-1619; DOI: https://doi.org/10.1124/dmd.111.040675
Twitter logo Facebook logo Mendeley logo

Jump to section

Advertisement